Cargando…
Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434874/ https://www.ncbi.nlm.nih.gov/pubmed/32811854 http://dx.doi.org/10.1038/s41598-020-68553-7 |
| _version_ | 1783572227954835456 |
|---|---|
| author | Kuo, Chun-Ting Chen, Chen-Lin Li, Chih-Chi Huang, Guan-Syuan Ma, Wei-Yuan Hsu, Wei-Fan Lin, Ching-Hung Lu, Yen-Shen Wo, Andrew M. |
| author_facet | Kuo, Chun-Ting Chen, Chen-Lin Li, Chih-Chi Huang, Guan-Syuan Ma, Wei-Yuan Hsu, Wei-Fan Lin, Ching-Hung Lu, Yen-Shen Wo, Andrew M. |
| author_sort | Kuo, Chun-Ting |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7434874 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74348742020-08-21 Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models Kuo, Chun-Ting Chen, Chen-Lin Li, Chih-Chi Huang, Guan-Syuan Ma, Wei-Yuan Hsu, Wei-Fan Lin, Ching-Hung Lu, Yen-Shen Wo, Andrew M. Sci Rep Author Correction Nature Publishing Group UK 2020-08-19 /pmc/articles/PMC7434874/ /pubmed/32811854 http://dx.doi.org/10.1038/s41598-020-68553-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Author Correction Kuo, Chun-Ting Chen, Chen-Lin Li, Chih-Chi Huang, Guan-Syuan Ma, Wei-Yuan Hsu, Wei-Fan Lin, Ching-Hung Lu, Yen-Shen Wo, Andrew M. Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models |
| title | Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models |
| title_full | Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models |
| title_fullStr | Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models |
| title_full_unstemmed | Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models |
| title_short | Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models |
| title_sort | author correction: immunofluorescence can assess the efficacy of mtor pathway therapeutic agent everolimus in breast cancer models |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434874/ https://www.ncbi.nlm.nih.gov/pubmed/32811854 http://dx.doi.org/10.1038/s41598-020-68553-7 |
| work_keys_str_mv | AT kuochunting authorcorrectionimmunofluorescencecanassesstheefficacyofmtorpathwaytherapeuticagenteverolimusinbreastcancermodels AT chenchenlin authorcorrectionimmunofluorescencecanassesstheefficacyofmtorpathwaytherapeuticagenteverolimusinbreastcancermodels AT lichihchi authorcorrectionimmunofluorescencecanassesstheefficacyofmtorpathwaytherapeuticagenteverolimusinbreastcancermodels AT huangguansyuan authorcorrectionimmunofluorescencecanassesstheefficacyofmtorpathwaytherapeuticagenteverolimusinbreastcancermodels AT maweiyuan authorcorrectionimmunofluorescencecanassesstheefficacyofmtorpathwaytherapeuticagenteverolimusinbreastcancermodels AT hsuweifan authorcorrectionimmunofluorescencecanassesstheefficacyofmtorpathwaytherapeuticagenteverolimusinbreastcancermodels AT linchinghung authorcorrectionimmunofluorescencecanassesstheefficacyofmtorpathwaytherapeuticagenteverolimusinbreastcancermodels AT luyenshen authorcorrectionimmunofluorescencecanassesstheefficacyofmtorpathwaytherapeuticagenteverolimusinbreastcancermodels AT woandrewm authorcorrectionimmunofluorescencecanassesstheefficacyofmtorpathwaytherapeuticagenteverolimusinbreastcancermodels |